Thrive Capital Leads Isomorphic Labs’ $2.1 Billion Series B

Gunderson Dettmer represented Thrive Capital as the lead investor in the $2.1 billion Series B financing of Isomorphic Labs, an AI-first drug design and development company. The round included participation from existing backers Alphabet and Google Ventures alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.

The new capital will be used for the continued development and deployment of Isomorphic Labs’ AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic. The funding will also allow the company to continue scaling its business globally in support of Isomorphic Labs’ long-term vision of applying AI-driven breakthroughs to the most complex biological and medical challenges and addressing the global burden of disease.

“We are humbled to have the opportunity to continue to support Isomorphic’s mission to solve all disease,” said Joshua Kushner, Founder and CEO of Thrive Capital, in the announcement of the transaction. “Over the past year, our conviction in the team has only deepened as they've made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design.”

The Gunderson deal team was led by Ryan Purcell and Sam Feldman and included Aaron Rubin, Cecilia Jeong, Emily Miller, Christian Hodges.